Login / Signup

Genome-wide association studies of exacerbations in children using long-acting beta2-agonists.

Elise Margaretha Adriana SlobLevi B RichardsSusanne J H VijverbergCristina LongoGerard H KoppelmanMariëlle W H PijnenburgElisabeth H D BelAnne H NeerincxEsther Herrera LuisJavier Perez-GarciaFook Tim ChewYang Yie SioAnand K AndiappanStephen W TurnerSomnath MukhopadhyayColin N A PalmerDaniel HawcuttAndrea L JorgensenEsteban G BurchardNatalia Hernandez-PachecoMaria Pino-YanesAnke H Maitland-van der Zee
Published in: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2021)
No strong effects of single nucleotide polymorphisms (SNPs) on exacerbations during LABA use were identified. We identified two loci (TBX3 and EPHA7) that were previously implicated in the response to short-acting beta2-agonists (SABA). These loci merit further investigation in response to LABA and SABA use.
Keyphrases
  • genome wide association
  • chronic obstructive pulmonary disease
  • cystic fibrosis
  • young adults
  • genome wide
  • case control
  • gene expression
  • dna methylation
  • genome wide association study